share_log

S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

S-8:员工福利计划证券登记
美股SEC公告 ·  04/18 12:36
Moomoo AI 已提取核心信息
180 Life Sciences Corp., a biotechnology company based in Palo Alto, California, has filed a Registration Statement on Form S-8 with the U.S. Securities and Exchange Commission (SEC) on April 17, 2024. The filing is intended to register an additional 198,943 shares of the company's common stock under its 2022 Omnibus Incentive Plan, following an amendment that increased the number of shares reserved for issuance. This move comes after the company's previous filings on August 9, 2022, and August 30, 2023. The newly registered shares are designated for employee incentives, aiming to attract and retain talent by offering stock options and restricted stock. The registration incorporates by reference several of the company's previously filed SEC documents, including the Annual Report for the year ended December 31, 2023. The company's Chief Executive Officer, James N. Woody, has signed the registration statement, affirming the company's compliance with the requirements for filing on Form S-8.
180 Life Sciences Corp., a biotechnology company based in Palo Alto, California, has filed a Registration Statement on Form S-8 with the U.S. Securities and Exchange Commission (SEC) on April 17, 2024. The filing is intended to register an additional 198,943 shares of the company's common stock under its 2022 Omnibus Incentive Plan, following an amendment that increased the number of shares reserved for issuance. This move comes after the company's previous filings on August 9, 2022, and August 30, 2023. The newly registered shares are designated for employee incentives, aiming to attract and retain talent by offering stock options and restricted stock. The registration incorporates by reference several of the company's previously filed SEC documents, including the Annual Report for the year ended December 31, 2023. The company's Chief Executive Officer, James N. Woody, has signed the registration statement, affirming the company's compliance with the requirements for filing on Form S-8.
总部位于加利福尼亚州帕洛阿尔托的生物技术公司180 Life Sciences Corp. 已于2024年4月17日向美国证券交易委员会(SEC)提交了S-8表格的注册声明。该文件旨在根据其2022年综合激励计划再注册198,943股公司普通股,此前一项修正案增加了预留发行的股票数量。此举是在该公司先前于2022年8月9日和2023年8月30日提交申报之后采取的。新注册的股票专门用于激励员工,旨在通过提供股票期权和限制性股票来吸引和留住人才。该注册以引用方式纳入了该公司先前向美国证券交易委员会提交的几份文件,包括截至2023年12月31日的年度报告。该公司首席执行官詹姆斯·伍迪签署了注册声明,确认公司遵守了提交S-8表格的要求。
总部位于加利福尼亚州帕洛阿尔托的生物技术公司180 Life Sciences Corp. 已于2024年4月17日向美国证券交易委员会(SEC)提交了S-8表格的注册声明。该文件旨在根据其2022年综合激励计划再注册198,943股公司普通股,此前一项修正案增加了预留发行的股票数量。此举是在该公司先前于2022年8月9日和2023年8月30日提交申报之后采取的。新注册的股票专门用于激励员工,旨在通过提供股票期权和限制性股票来吸引和留住人才。该注册以引用方式纳入了该公司先前向美国证券交易委员会提交的几份文件,包括截至2023年12月31日的年度报告。该公司首席执行官詹姆斯·伍迪签署了注册声明,确认公司遵守了提交S-8表格的要求。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息